Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Operating Expenses (2022 - 2024)

Amylyx Pharmaceuticals (AMLX) has 3 years of Other Operating Expenses data on record, last reported at $37.0 million in Q3 2024.

  • For Q3 2024, Other Operating Expenses rose 609.31% year-over-year to $37.0 million; the TTM value through Jun 2025 reached $37.0 million, down 73.26%, while the annual FY2024 figure was $160.8 million, 532.19% up from the prior year.
  • Other Operating Expenses reached $37.0 million in Q3 2024 per AMLX's latest filing, up from $7.4 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $116.4 million in Q1 2024 and bottomed at $172000.0 in Q3 2022.
  • Average Other Operating Expenses over 3 years is $21.0 million, with a median of $5.6 million recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: soared 2933.72% in 2023, then surged 32.94% in 2024.
  • A 3-year view of Other Operating Expenses shows it stood at $2.8 million in 2022, then soared by 231.8% to $9.4 million in 2023, then soared by 295.43% to $37.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $37.0 million in Q3 2024, $7.4 million in Q2 2024, and $116.4 million in Q1 2024.